Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.